Another possibility, however, is that other downstream mechanisms, such as glutamatergic overactivity, could play a more dominant role in generating severe dyskinesias, and therefore, the combined use of a 5-HT1A agonist and an NMDA antagonist may be needed. Here, HTR1A is linked to Dyskinesia.